Danimer Scientific Announces Fourth Quarter and Full Year 2022 Results

-- Results In-Line with March 20 Preannouncement --

-- Issues FY23 Guidance with Expectation for Accelerating Growth and Margin Improvement --

--Kentucky Facility Fully Commissioned and Achieving Throughput and Efficiency Targets --

-- Announces Submission of Part II Application for DoE Loan Guarantee Program --

BAINBRIDGE, Ga.--()--Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or the “Company”), a leading next generation bioplastics company focused on the development and production of biodegradable materials, announced today financial results for its fourth quarter and full year, ended December 31, 2022.

Stephen E. Croskrey, Chairman and Chief Executive Officer of Danimer, commented, “We are pleased to have achieved results consistent with our guidance for 2022, excited for the year ahead and focused on leveraging our global market-leadership position in PHA-based materials to drive value to our customers, partners and shareholders. Our Kentucky facility, now fully commissioned, is the first commercial scale production facility for highly engineered PHA-based materials in the world. We are confident that, as this year progresses, it will become increasingly clear that we have all the capabilities and advantages necessary to begin to disrupt the large, entrenched position of polluting plastics in markets around the world.”

Mr. Croskrey continued, “Our unique, high-performance biodegradable resins and the manufacturing capabilities to produce them at scale are the result of decades of investment and advances in biotechnology, process engineering and material science. We, along with a growing number of committed customers and partners, are poised to meet the call from consumers for environmentally responsible solutions and a range of stringent new standards for packaging that are rapidly emerging in the United States, Europe and many other important international markets. We believe our recently completed financing transaction enhances operational liquidity and ensures an open runway as we work to fully utilize the capacity now available to us in Winchester, Kentucky.”

All major processes and production equipment in the Company’s Kentucky facility have now been successfully tested and commissioned for operation and are performing to expected or better-than-expected levels of throughput. The Company continues to have confidence that it can achieve annual production capacity for approximately 32.5 million pounds of neat PHA which, after blending and extrusion, would comprise roughly 65 million pounds of finished resin for shipment to customers. At current average pricing and mix, 65 million pounds of finished product from the Kentucky facility would generate estimated revenues to the Company of approximately $190 million.

Danimer commented that it has submitted its Part II Application for the U.S. Department of Energy (DOE) Title XVII Loan Guarantee Program for its greenfield manufacturing facility in Bainbridge, Georgia. At full utilization of its design capacity this facility is forecasted to support approximately $400 million of revenues from PHA-based formulated resins which, combined with our Kentucky facility, would enable a total of $590 million of annual revenues.

Mr. Croskrey concluded, “We have also begun commissioning of our demonstration-scale facility that showcases a highly efficient catalytic production pathway to Rinnovo®, a PHA with improved flexibility and barrier properties. We are in advanced discussions intended to form potentially powerful partnerships to take advantage of the door we have opened to low-cost PHA-based materials.

Fourth Quarter 2022 Financial Highlights:

  • Revenues were $15.3 million in the fourth quarter of 2022 compared to $17.7 million in the fourth quarter of 2021. A $1.6 million reduction in product revenue was primarily the result of an unfavorable shift in the timing of PHA-based resin sales to a large customer and lower PLA-based resin sales due to the cessation of shipments to customers affected by the conflict in Ukraine. Services revenue of $0.8 million compared to $1.7 million reflects the completion of long-term funded R&D projects over the course of the year with customers now moving to commercialize those investments.
  • Gross profit was $(2.7) million compared to $(2.4) million in the fourth quarter of 2021. Adjusted gross profit was $2.6 million compared to $0.4 million in the fourth quarter of 2021. The improvement in adjusted gross profit reflects a favorable shift in the sales mix that more than offset the impact of reduced revenues.
  • Net loss for the fourth quarter was $(28.1) million compared with $(12.4) million in the prior year period.
  • Adjusted EBITDA improved to $(8.6) million in the fourth quarter of 2022 compared to $(10.2) million in the fourth quarter of 2021, due primarily to the above-mentioned improvements in gross profit.

Full Year 2022 Financial Highlights:

  • Revenues were $53.2 million for the full year of 2022 compared to $58.7 million in the prior year. PHA-related sales grew by 34 percent over the prior year and represented 53 percent of 2022 revenue. PLA-based product sales declined $9.9 million from the prior year, which included $9.1 million of shipments to certain customers that sell product in Ukraine, which did not recur in 2022 due to the ongoing war there.
  • Gross profit for 2022 was $(10.4) million compared to $0.9 million for the prior period. Adjusted gross profit was $4.4 million in 2022 compared to $11.0 million in 2021, primarily driven by an increased mix of PHA-based resins, which currently have lower margins due to the cost of increased capacity compared to the prior year.
  • Full-year 2022 net loss was $(179.8) million, which included a charge of $(62.7) million for goodwill impairment in the third quarter.
  • Full-year 2022 Adjusted EBITDA was $(45.0) million, consistent with the guidance range the Company first provided in May of 2022 and its most recent guidance of $(45.0) million to $(40.0) million.
  • Cash and cash equivalents at year-end was $62.8 million, consistent with the Company’s most recent guidance of $60 million to $65 million.
  • Full-year capital expenditures were $164.5 million, consistent with the Company’s most recent guidance of $165 million to $170 million.

Capital Structure

At December 31, 2022, the Company reported total debt outstanding of $288.4 million, which included approximately $45.7 million dollars of low-interest New Markets Tax Credit loans that the Company expects will be forgiven beginning in 2026.

On March 20, 2023, the Company announced a new senior secured term loan with an aggregate principal amount of $130 million that expands its capital structure, significantly improves its near-term liquidity position, and enables it to maintain strategic and operational flexibility as it executes its growth strategy. The Company noted that the effects of this recent transaction are not reflected in its December 31, 2022, financial statements.

Outlook

Michael Hajost, Danimer’s Chief Financial Officer, commented, “We are intently focused on revenue growth, which we expect to accelerate starting in our second quarter. As a result, we expect improving operating margins and operating cash flow as we move through the year.”

For the full year 2023, the Company today provided the following guidance:

  • Full-year Adjusted EBITDA is expected to be in the range of $(23) million to $(31) million. The improvement in Adjusted EBITDA compared to the $(45.0) million reported for 2022 is expected to result primarily from revenue growth in PHA-based resins and the related benefits of scale captured by the Company’s Kentucky manufacturing operations. In addition, the Company’s initiatives to improve efficiency and reduce costs are expected to have a favorable full-year impact on both R&D and SG&A expenses.
  • Full-year capital expenditures are anticipated to be in the range of $26 million to $31 million, primarily to support existing commitments related to the Bainbridge greenfield facility. The Company noted that it would expect to modify this spending estimate in the event financing is achieved later this year, particularly the U.S. Department of Energy (DOE) Title XVII Loan Guarantee Program. Other capital projects within the year include projected facility maintenance, completion of our Rinnovo® demonstration plant and spending related to information systems initiatives.

Webcast, Conference Call and 10-K Filing

The Company will host a webcast and conference call today, Tuesday, March 28, 2023, at 5:00 p.m. Eastern time to review fourth quarter and full-year 2022 results, discuss recent events and conduct a question-and-answer session. The live webcast of the conference call can be accessed on the Investor Relations section of the Company’s website at https://ir.danimerscientific.com. For those unable to access the webcast, the conference call will be accessible domestically or internationally, by dialing 1-877-407-9208 or 1-201-493-6784, respectively. Upon dialing in, please request to join the Danimer Scientific Full Year 2022 Earnings Conference Call. The archived webcast will be available for replay on the Company's website after the call.

About Danimer Scientific

Danimer is a pioneer in creating more sustainable, more natural ways to make plastic products. For more than a decade, its renewable and sustainable biopolymers have helped create plastic products that are biodegradable and compostable and return to nature instead of polluting our lands and waters. Danimer’s technology can be found in a vast array of plastic end products that people use every day. Applications for its biopolymers include additives, aqueous coatings, fibers, filaments, films and injection-molded articles, among others. Danimer holds more than 430 granted patents and pending patent applications in more than 20 countries for a range of manufacturing processes and biopolymer formulations. For more information, visit https://danimerscientific.com.

Forward-Looking Statements

Please note that in this press release we may use words such as “appears,” “anticipates,” “believes,” “plans,” “expects,” “intends,” “future,” and similar expressions which constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding our expectations for full year 2023 capital expenditures, Adjusted EBITDA and cash balances. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve a number of risks and uncertainties. We caution that forward-looking statements are not guarantees and that actual results could differ materially from those expressed or implied in the forward-looking statements. Potential risks and uncertainties that could cause the actual results of operations or financial condition of the Company to differ materially from those expressed or implied by forward-looking statements in this release include, but are not limited to, the overall level of consumer demand on our products; general economic conditions and other factors affecting consumer confidence, preferences, and behavior; disruption and volatility in the global currency, capital, and credit markets; the financial strength of the Company's customers; the Company's ability to implement its business strategy, including, but not limited to, its ability to expand its production facilities and plants to meet customer demand for its products and the timing thereof; risks relating to the uncertainty of the projected financial information with respect to the Company; the ability of the Company to execute and integrate acquisitions; changes in governmental regulation, legislation or public opinion relating to our products; the Company’s exposure to product liability or product warranty claims and other loss contingencies; disruptions and other impacts to the Company’s business, as a result of the COVID-19 global pandemic and government actions and restrictive measures implemented in response; stability of the Company’s manufacturing facilities and suppliers, as well as consumer demand for our products, in light of disease epidemics and health-related concerns such as the COVID-19 global pandemic; the impact on our business, operations and financial results from the ongoing conflict in Ukraine; the impact that global climate change trends may have on the Company and its suppliers and customers; the Company's ability to protect patents, trademarks and other intellectual property rights; any breaches of, or interruptions in, our information systems; the ability of our information technology systems or information security systems to operate effectively, including as a result of security breaches, viruses, hackers, malware, natural disasters, vendor business interruptions or other causes; our ability to properly maintain, protect, repair or upgrade our information technology systems or information security systems, or problems with our transitioning to upgraded or replacement systems; the impact of adverse publicity about the Company and/or its brands, including without limitation, through social media or in connection with brand damaging events and/or public perception; fluctuations in the price, availability and quality of raw materials and contracted products as well as foreign currency fluctuations; our ability to utilize potential net operating loss carryforwards; and changes in tax laws and liabilities, tariffs, legal, regulatory, political and economic risks. More information on potential factors that could affect the Company's financial results is included from time to time in the Company's public reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. All forward-looking statements included in this press release are based upon information available to the Company as of the date of this press release, and speak only as of the date hereof. We assume no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release.

 

Danimer Scientific, Inc.

Condensed Consolidated Balance Sheets

 

 

 

December 31,

 

December 31,

(in thousands, except share and per share data)

 

2022

 

2021

Assets:

 

 

 

 

Current assets:

 

 

 

 

Cash and cash equivalents

 

$

62,792

 

 

$

286,487

 

Accounts receivable, net

 

 

17,989

 

 

 

17,149

 

Other receivables, net

 

 

1,635

 

 

 

3,836

 

Inventories, net

 

 

32,743

 

 

 

24,573

 

Prepaid expenses and other current assets

 

 

5,225

 

 

 

4,737

 

Contract assets, net

 

 

4,687

 

 

 

3,576

 

Total current assets

 

 

125,071

 

 

 

340,358

 

 

 

 

 

 

Property, plant and equipment, net

 

 

453,949

 

 

 

316,181

 

Intangible assets, net

 

 

80,941

 

 

 

84,659

 

Goodwill

 

 

-

 

 

 

62,649

 

Right-of-use assets

 

 

19,028

 

 

 

19,240

 

Leverage loans receivable

 

 

31,446

 

 

 

13,408

 

Restricted cash

 

 

1,609

 

 

 

481

 

Loan fees

 

 

-

 

 

 

1,397

 

Other assets

 

 

226

 

 

 

224

 

Total assets

 

$

712,270

 

 

$

838,597

 

 

 

 

 

 

Liabilities and Stockholders' Equity:

 

 

 

 

Current liabilities:

 

 

 

 

Accounts payable

 

$

14,977

 

 

$

20,790

 

Accrued liabilities

 

 

5,001

 

 

 

18,777

 

Unearned revenue and contract liabilities

 

 

-

 

 

 

214

 

Current portion of lease liability

 

 

3,337

 

 

 

3,337

 

Current portion of long-term debt, net

 

 

1,972

 

 

 

357

 

Total current liabilities

 

 

25,287

 

 

 

43,475

 

 

 

 

 

 

Private warrants liability

 

 

212

 

 

 

9,578

 

Long-term lease liability, net

 

 

22,114

 

 

 

22,693

 

Long-term debt, net

 

 

286,398

 

 

 

260,934

 

Deferred income taxes

 

 

200

 

 

 

1,014

 

Other long-term liabilities

 

 

447

 

 

 

638

 

Total liabilities

 

$

334,658

 

 

$

338,332

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

Common stock, $0.0001 par value; 200,000,000 shares authorized: 101,804,454 and 100,687,820 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively

 

$

10

 

 

$

10

 

Additional paid-in capital

 

 

676,250

 

 

 

619,145

 

Accumulated deficit

 

 

(298,648

)

 

 

(118,890

)

Total stockholders’ equity

 

 

377,612

 

 

 

500,265

 

Total liabilities and stockholders’ equity

 

$

712,270

 

 

$

838,597

 

 

Danimer Scientific, Inc.

Condensed Consolidated Statements of Operations

 

 

 

Three Months Ended
December 31,

 

Years Ended
December 31,

(in thousands, except share and per share data)

 

2022

 

2021

 

2022

 

2021

 

 

 

 

 

 

 

 

 

Revenue:

 

 

 

 

 

 

 

 

Products

 

$

14,530

 

 

$

16,054

 

 

$

48,420

 

 

$

50,769

 

Services

 

 

794

 

 

 

1,674

 

 

 

4,798

 

 

 

7,980

 

Total revenue

 

 

15,324

 

 

 

17,728

 

 

 

53,218

 

 

 

58,749

 

 

 

 

 

 

 

 

 

 

Costs and expenses:

 

 

 

 

 

 

 

 

Cost of revenue

 

 

18,026

 

 

 

20,080

 

 

 

63,632

 

 

 

57,865

 

Selling, general and administrative

 

 

19,547

 

 

 

24,212

 

 

 

81,589

 

 

 

80,004

 

Research and development

 

 

7,470

 

 

 

8,666

 

 

 

31,939

 

 

 

20,270

 

Loss on sale of assets

 

 

-

 

 

 

49

 

 

 

1

 

 

 

82

 

Impairment of long-lived assets

 

 

-

 

 

 

-

 

 

 

63,491

 

 

 

-

 

Total costs and expenses

 

 

45,043

 

 

 

53,007

 

 

 

240,652

 

 

 

158,221

 

Loss from operations

 

 

(29,719

)

 

 

(35,279

)

 

 

(187,434

)

 

 

(99,472

)

Nonoperating income (expense)

 

 

 

 

 

 

 

 

Gain on remeasurement of private warrants

 

 

752

 

 

 

21,332

 

 

 

9,366

 

 

 

27,767

 

Interest, net

 

 

474

 

 

 

(247

)

 

 

(1,723

)

 

 

(763

)

Gain on forgiveness of debt

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,776

 

Loss on loan extinguishment

 

 

-

 

 

 

-

 

 

 

(1,500

)

 

 

(2,604

)

Other, net

 

 

399

 

 

 

(62

)

 

 

723

 

 

 

(44

)

Total nonoperating income (expense):

 

 

1,625

 

 

 

21,023

 

 

 

6,866

 

 

 

26,132

 

Loss before income taxes

 

 

(28,094

)

 

 

(14,256

)

 

 

(180,568

)

 

 

(73,340

)

Income taxes

 

 

43

 

 

 

1,810

 

 

 

810

 

 

 

13,233

 

Net loss

 

$

(28,051

)

 

$

(12,446

)

 

$

(179,758

)

 

$

(60,107

)

 

 

 

 

 

 

 

 

 

Basic net loss per share

 

$

(0.28

)

 

$

(0.12

)

 

$

(1.78

)

 

$

(0.65

)

 

 

 

 

 

 

 

 

 

Weighted average number of shares used to compute:

 

 

 

 

 

 

 

 

Basic and diluted net loss per share

 

 

101,397,811

 

 

 

100,360,592

 

 

 

101,095,341

 

 

 

93,078,004

 

 

Danimer Scientific, Inc.

Condensed Consolidated Statements of Cash Flows

 

 

Years Ended

 

 

December 31,

(in thousands)

 

2022

 

2021

Cash flows from operating activities:

 

 

 

 

Net loss

 

$

(179,758

)

 

$

(60,107

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

Impairment of long-lived assets

 

 

63,491

 

 

 

-

 

Stock-based compensation

 

 

56,958

 

 

 

55,270

 

Depreciation and amortization

 

 

20,453

 

 

 

11,674

 

Amortization of debt issuance costs

 

 

2,104

 

 

 

480

 

Bad debt provision

 

 

1,904

 

 

 

524

 

Loss on extinguishment of debt

 

 

1,500

 

 

 

1,939

 

Contract asset reserve

 

 

1,216

 

 

 

-

 

Gain on remeasurement of private warrants

 

 

(9,366

)

 

 

(27,767

)

Deferred income taxes

 

 

(814

)

 

 

(13,233

)

Amortization of right-of-use assets and lease liability

 

 

(367

)

 

 

(1,040

)

Gain on forgiveness of debt

 

 

-

 

 

 

(1,776

)

Other

 

 

163

 

 

 

471

 

Changes in operating assets and liabilities, net of effects of acquisition:

 

 

 

 

Accounts receivable

 

 

(3,056

)

 

 

(11,359

)

Other receivables

 

 

2,513

 

 

 

-

 

Inventories, net

 

 

(11,170

)

 

 

(9,799

)

Prepaid expenses and other current assets

 

 

2,662

 

 

 

(4,336

)

Contract assets

 

 

(2,328

)

 

 

(2,110

)

Other assets

 

 

(4

)

 

 

(75

)

Accounts payable

 

 

(1,565

)

 

 

2,048

 

Accrued and other long-term liabilities

 

 

(6,159

)

 

 

(1,526

)

Unearned revenue and contract liabilities

 

 

(214

)

 

 

(2,241

)

Net cash used in operating activities

 

 

(61,837

)

 

 

(62,963

)

Cash flows from investing activities:

 

 

 

 

Purchases of property, plant and equipment and intangible assets

 

 

(164,486

)

 

 

(185,411

)

Investment in leverage loans receivable related to NMTC financing

 

 

(18,037

)

 

 

-

 

Acquisition of Novomer, net of cash acquired

 

 

(14

)

 

 

(151,179

)

Proceeds from sales of property, plant and equipment

 

 

55

 

 

 

422

 

Net cash used in investing activities

 

 

(182,482

)

 

 

(336,168

)

Cash flows from financing activities:

 

 

 

 

Proceeds from long-term debt

 

 

24,700

 

 

 

240,245

 

Cash paid for debt issuance costs

 

 

(1,591

)

 

 

(10,424

)

Principal payments on long-term debt

 

 

(1,504

)

 

 

(27,162

)

Proceeds from employee stock purchase plan

 

 

377

 

 

 

106

 

Proceeds from issuance of common stock, net of issuance costs

 

 

(236

)

 

 

(890

)

Proceeds from exercise of stock options

 

 

215

 

 

 

2,899

 

Employee taxes related to stock-based compensation

 

 

(154

)

 

 

(1,728

)

Cost related to warrants

 

 

(55

)

 

 

-

 

Proceeds from exercise of warrants, net of issuance costs

 

 

-

 

 

 

138,196

 

Purchase of capped call options

 

 

-

 

 

 

(35,040

)

Net cash provided by financing activities

 

 

21,752

 

 

 

306,202

 

Net decrease in cash and cash equivalents and restricted cash

 

 

(222,567

)

 

 

(92,929

)

Cash and cash equivalents and restricted cash-beginning of period

 

 

286,968

 

 

 

379,897

 

Cash and cash equivalents and restricted cash-end of period

 

$

64,401

 

 

$

286,968

 

 

Non-GAAP Financial Measures

This press release includes the non-GAAP financial measures “Adjusted EBITDA”, “Adjusted EBITDAR”, “Adjusted gross profit” and "Adjusted gross margin". Danimer management views these metrics as a useful way to look at the performance of its operations between periods and to exclude decisions on capital investment and financing that might otherwise impact the review of profitability of the business based on present market conditions.

Adjusted EBITDA is defined as net income or loss plus net interest expense, income taxes, depreciation and amortization, as adjusted to add back certain charges or gains that Danimer may record each period such as remeasurement of private warrants, stock-based compensation expense, as well as non-recurring charges such as (i) asset disposal gains or losses as well as other significant gains or losses such as debt extinguishments and impairment of goodwill; (ii) legal settlements; or (iii) other discrete non-recurring items. Danimer believes these items are not considered an indicator of ongoing performance. Adjusted EBITDA is not a measure of performance defined in accordance with GAAP. The measure is used as a supplement to GAAP results in evaluating certain aspects of Danimer’s business, as described below.

Adjusted EBITDAR is defined as Adjusted EBITDA plus rent expense.

Adjusted gross profit is defined as gross profit plus depreciation, PLA additive inventory reserve, stock-based compensation and rent expense.

Adjusted gross margin is defined as adjusted gross profit divided by total revenue.

Danimer believes that each of Adjusted EBITDA, Adjusted EBITDAR, Adjusted gross profit and Adjusted gross margin is useful to investors in evaluating the Company’s performance because each measure considers the performance of the Company’s operations, excluding decisions made with respect to capital investment, financing and other non-recurring charges as outlined in the preceding paragraph. Danimer believes these non-GAAP metrics offer additional financial information that, when coupled with the GAAP results and the reconciliation to GAAP results, provides a more complete understanding of its results of operations and the factors and trends affecting its business.

Adjusted EBITDA, Adjusted EBITDAR, Adjusted gross profit and Adjusted gross margin should not be considered as an alternative to net income or loss as an indicator of its performance or as alternatives to any other measure prescribed by GAAP as there are limitations to using such non-GAAP measures. Although Danimer believes that Adjusted EBITDA, Adjusted EBITDAR, Adjusted gross profit and Adjusted gross margin may enhance an evaluation of its operating performance based on recent revenue generation and product/overhead cost control because it excludes the impact of prior decisions made about capital investment, financing and other expenses, (i) other companies in Danimer’s industry may define Adjusted EBITDA, Adjusted EBITDAR, Adjusted gross profit and Adjusted gross margin differently than Danimer does and, as a result, they may not be comparable to similarly titled measures used by other companies in its industry, and (ii) Adjusted EBITDA, Adjusted EBITDAR, Adjusted gross profit and Adjusted gross margin exclude certain financial information that some may consider important in evaluating Danimer’s performance.

Danimer compensates for these limitations by providing disclosure of the differences between Adjusted EBITDA, Adjusted EBITDAR, Adjusted gross profit and Adjusted gross margin and GAAP results, including providing a reconciliation to GAAP results, to enable investors to perform their own analysis of Danimer’s operating results. Because GAAP financial measures on a forward-looking basis are not accessible, and reconciling information is not available without unreasonable effort, reconciliations to GAAP financial measures are not provided for forward-looking non-GAAP measures. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.

 

Danimer Scientific, Inc.

Reconciliation of Adjusted EBITDAR and Adjusted EBITDA to Net (Loss) Income (Unaudited)

 

 

 

Three Months Ended
December 31,

 

Twelve Months Ended
December 31,

 

 

2022

 

2021

 

2022

 

2021

(in thousands)

 

 

 

 

 

 

 

 

Net loss

 

$

(28,051

)

 

$

(12,446

)

 

$

(179,758

)

 

$

(60,107

)

Stock-based compensation

 

 

14,218

 

 

 

20,055

 

 

 

56,768

 

 

 

55,908

 

Depreciation and amortization

 

 

7,281

 

 

 

4,185

 

 

 

20,453

 

 

 

11,674

 

Gain on remeasurement of private warrants

 

 

(752

)

 

 

(21,332

)

 

 

(9,366

)

 

 

(27,767

)

Interest (income) expense, net

 

 

(474

)

 

 

247

 

 

 

1,723

 

 

 

763

 

Income taxes

 

 

(43

)

 

 

(1,810

)

 

 

(810

)

 

 

(13,233

)

Inventory reserve

 

 

(495

)

 

 

-

 

 

 

-

 

 

 

-

 

Litigation and other legal related

 

 

146

 

 

 

48

 

 

 

2,082

 

 

 

1,232

 

Impairment of goodwill

 

 

-

 

 

 

-

 

 

 

62,663

 

 

 

-

 

Transaction related

 

 

-

 

 

 

199

 

 

 

-

 

 

 

3,974

 

Public company transition costs

 

 

-

 

 

 

561

 

 

 

481

 

 

 

4,024

 

Loss on sale of assets

 

 

-

 

 

 

49

 

 

 

1

 

 

 

82

 

Gain on forgiveness of debt

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(1,776

)

Loss on loan extinguishment

 

 

-

 

 

 

-

 

 

 

1,500

 

 

 

2,604

 

Other, net

 

 

(399

)

 

 

62

 

 

 

(723

)

 

 

44

 

Adjusted EBITDA

 

$

(8,569

)

 

$

(10,182

)

 

$

(44,986

)

 

$

(22,578

)

Rent

 

 

875

 

 

 

845

 

 

 

3,511

 

 

 

2,488

 

Adjusted EBITDAR

 

$

(7,694

)

 

$

(9,337

)

 

$

(41,475

)

 

$

(20,090

)

Reconciliation of Adjusted Gross Profit to Gross Profit (Unaudited)

 

 

 

Three Months Ended
December 31,

 

Twelve Months Ended
December 31,

 

 

2022

 

2021

 

2022

 

2021

(in thousands)

 

 

 

 

 

 

 

 

Total revenue

 

$

15,324

 

 

$

17,728

 

 

$

53,218

 

 

$

58,749

 

Cost of revenue

 

 

18,026

 

 

 

20,080

 

 

 

63,632

 

 

 

57,865

 

Gross profit

 

 

(2,702

)

 

 

(2,352

)

 

 

(10,414

)

 

 

884

 

Depreciation

 

 

5,161

 

 

 

2,142

 

 

 

12,249

 

 

 

8,041

 

Rent

 

 

626

 

 

 

581

 

 

 

2,506

 

 

 

1,917

 

Inventory reserve

 

 

(495

)

 

 

-

 

 

 

-

 

 

 

-

 

Stock-based compensation

 

 

-

 

 

 

29

 

 

 

60

 

 

 

109

 

Adjusted gross profit

 

$

2,590

 

 

$

400

 

 

$

4,401

 

 

$

10,951

 

 

 

 

 

 

 

 

 

 

Adjusted gross margin

 

 

16.9

%

 

 

2.3

%

 

 

8.3

%

 

 

18.6

%

 

Contacts

Investors
James Palczynski
Phone: 415-876-8429
ir@danimer.com

Media
Anthony Priwer
apriwer@daltonagency.com
Phone: 615-515-4892

Contacts

Investors
James Palczynski
Phone: 415-876-8429
ir@danimer.com

Media
Anthony Priwer
apriwer@daltonagency.com
Phone: 615-515-4892